Søgeresultater - Victoria Lock

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors

    A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors af Daruka Mahadevan, Ruth Plummer, Matthew Squires, Diane Rensvold, Sandra Kurtin, Chris Pretzinger, Tomislav Dragovich, Joëlla W. Adams, Victoria Lock, Donna-Michelle Smith, D. Von Hoff, Hilary Calvert

    Udgivet 2011
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  2. 2
    A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

    A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies af Hendrik‐Tobias Arkenau, Ruth Plummer, L. Rhoda Molife, David Olmos, Timothy A. Yap, Matthew Squires, Sara Lewis, Victoria Lock, Murray Yule, John F. Lyons, Hilary Calvert, Ian Judson

    Udgivet 2011
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  3. 3
    AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth

    AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth af Kyla M. Grimshaw, Lisa-Jane K. Hunter, Timothy A. Yap, Simon P. Heaton, Mike I. Walton, Steven J. Woodhead, Lynsey Fazal, Matthias Reule, Thomas G. Davies, Lisa C. A. Seavers, Victoria Lock, John F. Lyons, Neil T. Thompson, Paul Workman, Michelle D. Garrett

    Udgivet 2010
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  4. 4
    A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

    A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study af Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson, Bruce Morland, Martin Elliott, Quentin Campbell‐Hewson, Guy Makin, Sarah Halford, Gary D Acton, Philip Ross, Shamim Kazmi-Stokes, Victoria Lock, Ana Isabel Enríquez Rodríguez, John F. Lyons, Alan V. Boddy, Melanie J. Griffin, Murray Yule, Darren Hargrave

    Udgivet 2014
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:

Søgeredskaber: